Solutions...

Pricing & Access
Strategies

Optimal pricing strategies for development decisions and market access.

Read more

Conjoint
Research

Delivering conjoint that can handle the intricacies of the pharma market.

Read more

Forecasting
Software

Allowing leading pharma companies to build evidence-based forecasts fast and easily.

Read more

Launch Sequence
Simulators

Get your country launch sequence right. Capture full value in the face of international reference pricing.

Read more

Training
Courses

Industry-leading pricing-for-market-access and forecasting training.

Read more

Announcements

Update: Trump has asked for international reference pricing proposals

We recently posted a Quick Read on what we know about the potential introduction of international reference pricing (often abbreviated to IRP) in the USA.

Since then, Politico has published an article that claims the Trump administration has now asked for proposals to introduce a Most Favored Nation policy. Whereas before we were citing think tanks, now news outlets are suggesting the Trump administration itself is actively considering international reference pricing.

What does this mean for you?

If you were waiting for more clarity before taking action, wait no more. We are one step closer to a huge shakeup in the pharma pricing landscape.

Start preparing by simulating all possible USA IRP mechanisms to see the impact on your global revenues.

Get in touch to learn more about how we can help you. Or, read more about our IRP and launch sequence optimization simulators.

We tailor our services to your exact requirements

Get in touch with us and arrange a meeting

Inpharmation
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.